R1 RCM Inc

R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Murray, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

R1 RCM Inc (RCM) posts strong Q4 results, eyes Cloudmed growth

R1 RCM Inc (RCM) delivered robust financial performance in Q4 2022, focusing on operational excellence, technology investments, and customer engagement. Challenges include integration efforts and seasonality affecting incentive fees. The company is poised for growth with opportunities in Cloudmed expansion and AI utilization.

R1 RCM Inc (RCM) reports strong Q1 results and growth opportunities

R1 RCM Inc (RCM) delivered strong Q1 results, with a focus on operational improvements, robust Cloudmed growth, and positive financial outlook for 2023.
The company showcased resilience in stable patient self-pay trends, improving payer reimbursement timelines, and strategic capacity for onboarding new NPR, positioning itself for continued success.
Challenges include industry financial pressures, sustaining growth in legacy business, and managing operational costs effectively, requiring strategic adaptation and continuous innovation.
Opportunities lie in pipeline visibility for deals, sequential EBITDA growth, integration of Cloudmed capabilities, and strategic onboarding plans, offering avenues for expansion and profitability.

R1 RCM Inc reports robust Q2 earnings, eyes growth opportunities

R1 RCM Inc's Q2 performance was strong, with a focus on technology and operational enhancements. Challenges include revenue adjustments and workforce implications of automation. Opportunities lie in improved payer dynamics and growth through physician market focus and cross-selling.

R1 RCM Inc reports robust Q3 performance and eyes growth

R1 RCM Inc's Q3 earnings call highlighted strong financial performance, strategic priorities, and challenges in pediatric contracts and integration issues.
The company's focus on revenue optimization, leveraging technology, and partnership with Microsoft positions it well for growth opportunities within the customer base and offshoring initiatives.
While facing challenges in deal timings and debt repayment, R1 RCM Inc's emphasis on operational metrics, customer relationships, and workforce management presents avenues for continued success and industry leadership.

R1 RCM Inc reports robust Q4 earnings, eyes growth opportunities

R1 RCM Inc's Q4 2023 earnings call highlighted strong financial performance, strategic objectives for 2023, and a confident outlook for sustainable growth and shareholder value creation.
The company's emphasis on customer-centricity, AI integration, and operational efficiency underscores its strengths in revenue growth and market positioning.
While facing challenges in credit allowances and customer health, R1 RCM Inc aims to leverage opportunities in reduced costs, synergies from acquisitions, and strategic sales to drive future growth.

R1 RCM reports resilient Q1 performance post-cyberattack, eyes growth

R1 RCM showcased resilience in Q1 2024 despite the Change Healthcare cyberattack, focusing on growth strategies, operational excellence, and technology innovation.
The company faces challenges from the cyberattack impact on KPIs and vendor changes but sees opportunities in the managed care environment and customer engagement.
Overall, R1 RCM remains optimistic about transforming the industry through technology and expertise, with a strong market demand for its solutions.

R1 RCM Inc reports robust Q2 earnings amidst cyberattack challenges

R1 RCM Inc's Q2 2024 earnings call showcased strong financial performance, operational resilience in the face of cyberattacks, and a strategic focus on growth initiatives. The company faces challenges related to pending transactions and cyberattack impacts but sees opportunities in expanding its platform and leveraging technology for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

R1 RCM serves as a revenue cycle management partner for hospitals and healthcare systems regardless of the payment models, patient engagement strategies, or settings of care. The company uses a proven operating model based on the R1 Performance StackSM designed to fit seamlessly into any healthcare organization’s infrastructure and to enhance the patient experience, improve provider economics, and provide revenue predictability. R1 RCM was founded on 2003 and is based in Chicago, Illinois.

R1 RCM Inc. (RCM) delivered earnings and revenue surprises of -33.33% and 1.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

R1 RCM Inc. (RCM) Q2 Earnings Lag Estimates

Shares of R1 RCM (NASDAQ:RCM) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 100.00% over the past year to $0.06, which missed the estimate of $0.07.

R1 RCM: Q2 Earnings Insights

MURRAY, Utah, Aug. 03, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended June 30, 2021.

R1 RCM Reports Second Quarter 2021 Results; Raises 2021 Guidance

Former Microsoft Azure founding member and Starbucks Executive to Accelerate R1's Digital Growth and Innovation Former Microsoft Azure founding member and Starbucks Executive to Accelerate R1's Digital Growth and Innovation

R1 Appoints Jay Sreedharan as New Chief Technology and Digital Officer

MURRAY, Utah, July 15, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it expects to release financial results for the three months ended June 30, 2021 before market open on Tuesday, August 3, 2021.

R1 RCM to Release Second Quarter 2021 Results on August 3

CHICAGO, July 01, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it has completed the acquisition of VisitPay, the leading digital payment solution provider.

R1 Completes Acquisition of VisitPay

CHICAGO, May 26, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (“R1 RCM” or the “Company”) (NASDAQ: RCM) announced that it has priced the underwritten offering of 15,000,000 shares of its common stock by selling stockholders at a price to the public of $22.50 per share. The selling stockholders are TCP-ASC ACHI Series LLLP (“TCP-ASC”), a Delaware series limited liability limited partnership jointly owned by Ascension Health Alliance and investment funds affiliated with TowerBrook Capital Partners L.P., and Joseph Flanagan, the President and Chief Executive Officer of the Company. The underwriters will have a 30-day option to purchase up to an additional 2,250,000 shares of common stock from TCP-ASC. The offering is expected to close on June 1, 2021, subject to the satisfaction or waiver of customary closing conditions. R1 RCM is not selling any shares in the offering and will not receive any of the proceeds from the sale of common stock by the selling stockholders.

R1 RCM Announces Pricing of Secondary Offering of 15,000,000 Shares by Selling Stockholders

CHICAGO, May 25, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (“R1 RCM” or the “Company”) (NASDAQ: RCM) announced the commencement of an underwritten offering of an aggregate of 15,000,000 shares of its common stock by selling stockholders. The selling stockholders are TCP-ASC ACHI Series LLLP (“TCP-ASC”), a Delaware series limited liability limited partnership jointly owned by Ascension Health Alliance and investment funds affiliated with TowerBrook Capital Partners, L.P., and Joseph Flanagan, the President and Chief Executive Officer of the Company. The underwriters will have a 30-day option to purchase up to an additional 2,250,000 shares of common stock from TCP-ASC. R1 RCM is not selling any shares in the offering and will not receive any of the proceeds from the sale of common stock by the selling stockholders.

R1 RCM Announces Commencement of Secondary Offering by Selling Stockholders

R1 RCM Inc. (RCM) CEO Joe Flanagan on Q1 2021 Results - Earnings Call Transcript

Why R1 RCM Stock Is Tumbling Today

R1 RCM Inc. (RCM) delivered earnings and revenue surprises of -2270.00% and 1.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

R1 RCM Inc. (RCM) Reports Q1 Loss, Tops Revenue Estimates

Shares of R1 RCM (NASDAQ:RCM) fell 4.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 4840.00% year over year to ($2.37), which may not compare to the estimate of ($0.03).

Recap: R1 RCM Q1 Earnings

CHICAGO, May 04, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended March 31, 2021.

R1 RCM Reports First Quarter 2021 Results

Enhanced R1 technology solution to provide digital patient payment and billing experience across all settings of care Enhanced R1 technology solution to provide digital patient payment and billing experience across all settings of care

R1 Announces Agreement to Acquire VisitPay, the Leading Provider of Patient Financial Engagement Solutions

R1 and Ascension to transform the consumer experience in healthcare R1 and Ascension to transform the consumer experience in healthcare

R1 Announces Revenue Cycle Management Partnership Expansion and Extension with Ascension

CHICAGO, April 30, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at two upcoming investor conferences:

R1 RCM to Present at Two Upcoming Investor Conferences

Synchrony Financial

SYF vs. RCM: Which Stock Is the Better Value Option?

SYF or RCM: Which Is the Better Value Stock Right Now?

CHICAGO, April 20, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it expects to release financial results for the three months ended March 31, 2021 before market open on Tuesday, May 4, 2021.

R1 RCM to Release First Quarter 2021 Results on May 4

CHICAGO, April 19, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced the appointment of David Dill, president and chief executive officer of LifePoint Health, to the company's board of directors, effective April 18, 2021.

R1 Announces Appointment of David Dill to Board of Directors

CIXX vs. RCM: Which Stock Is the Better Value Option?

CIXX or RCM: Which Is the Better Value Stock Right Now?

The company is getting ever more entrenched in the healthcare sector, growing with their customers, adding new ones, and adding new solutions and through M&A.

R1 RCM Is Increasingly Entrenched In The U.S. Healthcare Sector, We See Further Upside

CHICAGO, March 09, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 23 at 10:45am ET.

R1 RCM to Present at the KeyBanc Life Sciences & MedTech Investor Forum

CHICAGO, March 01, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, released its inaugural Environmental, Social, and Governance (ESG) Report detailing R1's approach to ESG, corporate responsibility, and sustainability. As a trusted partner to its customers, and the patients and communities they serve, R1 built an ESG framework that aligns with the United Nations Sustainable Development Goals and demonstrates a commitment to transparency, accountability, and social responsibility to its stakeholders.

R1 RCM Issues Inaugural Environmental, Social, and Governance Report

Intercorp Financial Services Inc

IFS vs. RCM: Which Stock Is the Better Value Option?

IFS vs. RCM: Which Stock Should Value Investors Buy Now?

DexCom

Hexcel

Paycom Software

Toxic stocks usually carry huge debt load and are vulnerable to external shocks. They should be timely discarded from one's portfolio to avoid wealth erosion.

News for R1 RCM Inc Stock (RCM)